VNDA Vanda Pharmaceuticals
- 5.130
- +0.080+1.58%
Vanda Pharmaceuticals News
Vanda Pharmaceuticals Reports Mixed Q1 2024 Results, Misses Revenue Estimates
Earnings Call Summary | Vanda Pharmaceuticals(VNDA.US) Q1 2024 Earnings Conference
The following is a summary of the Vanda Pharmaceuticals, Inc. (VNDA) Q1 2024 Earnings Call Transcript:Financial Performance:Vanda Pharmaceuticals posted total revenues of $47.5 million for Q1 2024, re
Vanda Pharmaceuticals | 10-Q: Quarterly report
Q1 2024 Vanda Pharmaceuticals Inc Earnings Call
Exact Sciences Reports Q1 Loss, Joins Beyond Meat, Duolingo And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling around 100 points on Thursday.Shares of Exact Sciences Corporation (NASDAQ:EXAS) fell sharply in today's pre-market trading aft
Vanda Pharmaceuticals, Inc. (VNDA) Q1 2024 Earnings Call Transcript
Vanda Pharmaceuticals, Inc. (VNDA) Q1 2024 Earnings Call Transcript
Vanda Pharma Q1 2024 GAAP EPS $(0.07) Misses $0.05 Estimate, Sales $47.462M Miss $48.500M Estimate
Vanda Pharma (NASDAQ:VNDA) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $0.05 by 240 percent. The company reported quarterly sales of $47.462 million
Earnings Flash (VNDA) VANDA PHARMACEUTICALS Reports Q1 Revenue $47.5M
04:01 PM EDT, 05/08/2024 (MT Newswires) -- Earnings Flash (VNDA) VANDA PHARMACEUTICALS Reports Q1 Revenue $47.5M
Vanda Pharmaceuticals 1Q Loss/Shr 7c >VNDA
Vanda Pharmaceuticals 1Q Loss/Shr 7c >VNDA
Press Release: Vanda Pharmaceuticals Reports First Quarter 2024 Financial Results
Vanda Pharmaceuticals Reports First Quarter 2024 Financial Results PR Newswire WASHINGTON, May 8, 2024 -- Revenues for Q1 2024 were $47.5 million, an increase of 5% compared to Q4 2023
Vanda Pharmaceuticals 1Q Rev $47.5M >VNDA
Vanda Pharmaceuticals 1Q Rev $47.5M >VNDA
Vanda Pharmaceuticals 1Q Loss $4.15M >VNDA
Vanda Pharmaceuticals 1Q Loss $4.15M >VNDA
Sector Update: Health Care Stocks Stronger in Tuesday Afternoon Trading
Health care stocks rose Tuesday afternoon with the NYSE Health Care Index adding 0.8% and the Health Care Select Sector SPDR Fund (XLV) up 0.6%. The iShares Biotechnology ETF (IBB) fell 0.2%. In corpo
Sector Update: Health Care
Health care stocks rose Tuesday afternoon with the NYSE Health Care Index adding 0.8% and the Health Care Select Sector SPDR Fund (XLV) up 0.7%. The iShares Biotechnology ETF (IBB) was little changed.
Market Frenzy: Vanda Pharmaceuticals (VNDA) Shares Surge
After a revised takeover bid, Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) is currently witnessing a surge in its share price on the market. As of the last check during the current session, VNDA shares have escalated by 16.63% to reach $5.64. Vanda Pharmaceuticals (VNDA) has officially acknowledged receipt of an altered unsolicited proposition from Future Pak, ...
Vanda Pharmaceuticals Confirms Receipt of Revised Unsolicited Takeover Proposal From Future Pak
No Shareholder Action Required at This Time WASHINGTON, May 7, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") (Nasdaq: VNDA) today confirmed that it has received a revised
UPDATE 1-Future Pak Sweetens Buyout Offer for Vanda Pharmaceuticals
Vanda Pharmaceuticals Shares Are Trading Higher After Future Pak Increased Its Bid for the Company.
Vanda Pharmaceuticals Shares Are Trading Higher After Future Pak Increased Its Bid for the Company.
Future Pak Increases Bid For Vanda Pharmaceuticals To Include CVRs In Addition To $7.25-$7.75 Per Share In Cash; Offer Represents $11.62-$12.12 Per Share
Future Pak Increases Bid For Vanda Pharmaceuticals To Include CVRs In Addition To $7.25-$7.75 Per Share In Cash; Offer Represents $11.62-$12.12 Per Share
Vanda Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 8, 2024
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the first quarter 2024 on Wednesday, May 8, 2024, after ...
Analysis
Price Target
No Data
